ChemicalBook
Chinese Japanese Germany Korea

Ruxolitinib phosphate

Physical and Chemical Properties Approval for Use Side Effects
Ruxolitinib phosphate
Ruxolitinib phosphate structure
CAS No.
1092939-17-7
Chemical Name:
Ruxolitinib phosphate
Synonyms
INCB 018424;Ruxotinib phosphate;Jakafi (ruxolitinib);Ruxolitinib, Phosphate;INCB018424 (phosphate);INCB-018424 (phosphate);INCB 018424 (phosphate);Ruxolitinib, Phosphate Salt;Ruxolitinib phosphate, >=98%;Ruxolitinib phosphate(INCB018424)
CBNumber:
CB82509943
Molecular Formula:
C17H18N6.H3PO4
Formula Weight:
404.360201
MOL File:
1092939-17-7.mol

Ruxolitinib phosphate Properties

FDA UNII
436LRU32H5
SAFETY
  • Risk and Safety Statements
HS Code  29331990

Ruxolitinib phosphate price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 23215 Ruxolitinib (phosphate) ≥98% 1092939-17-7 1mg $25 2018-11-19 Buy
Cayman Chemical 23215 Ruxolitinib (phosphate) ≥98% 1092939-17-7 5mg $94 2018-11-19 Buy
Cayman Chemical 23215 Ruxolitinib (phosphate) ≥98% 1092939-17-7 10mg $163 2018-11-19 Buy
Cayman Chemical 23215 Ruxolitinib (phosphate) ≥98% 1092939-17-7 25mg $313 2018-11-19 Buy

Ruxolitinib phosphate Chemical Properties,Uses,Production

Physical and Chemical Properties

Ruxolitinib, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3- cyclopentylpropanenitrile phosphate, has a molecular weight of 404.36 kDa. Ruxolitinib is soluble in aqueous solutions at pH 1-8. Ruxolitinib tablets are stable at 20-25°C and tolerate brief exposures to temperatures outside this range, if they stay within 15-30°C.

Approval for Use

Ruxolitinib is an oral inhibitor of JAK1 and JAK2, which is approved for the treatment of myeloproliferative neoplasm-associated myelofibrosis, further myeloproliferative neoplasms, polycythemia vera and refractory cancer. In the USA, Canada and EU, ruxolitinib is approved for the treatment of patients with intermediate or high-risk PMF, post-PV MF or post-ET MF. In addition, ruxolitinib recently has been approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea, based on the results of Phase II and III clinical studies. To date, ruxolitinib has been approved for indications in MF in 83 countries.

Side Effects

Common side effects of ruxolitinib treatment include anaemia and thrombocytopenia. The decline of circulating erythrocytes following ruxolitinib treatment could result in part from stimulation of eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the cell surface. Cellular mechanisms involved in the execution of eryptosis include oxidative stress, Ca2+ entry with increase of cytosolic Ca2+ activity ([Ca2+]i), ceramide, decline of cytosolic ATP, caspases, stimulated activity of casein kinase 1α, Janus-activated kinase JAK3, protein kinase C, and p38 kinase, as well as impaired activity of AMP activated kinase AMPK, cGMP-dependent protein kinase, PAK2 kinase and sorafenib/sunitinib sensitive kinases.

Uses

The phosphate salt of Ruxolitinib (R702000). Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.

Definition

ChEBI: A phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essent al thrombocythemia myelofibrosis.

Ruxolitinib phosphate Preparation Products And Raw materials

Raw materials

Preparation Products


Ruxolitinib phosphate Suppliers

Global( 122)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Beijing Yibai Biotechnology Co., Ltd
0086-182-6772-3597
sales03@yibaibiotech.com CHINA 420 58
Capot Chemical Co.,Ltd.
+86-571-85586718
+86-571-85864795 sales@capotchem.com China 19927 60
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22626 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2543 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3015 60
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24698 60
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30050 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23977 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 linda@hubeijusheng.com CHINA 28235 58

Related articles


View Lastest Price from Ruxolitinib phosphate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2020-04-23 Ruxolitinib phosphate
1092939-17-7
US $0.10 / KG 1KG 99.0% 1000 tons Shaanxi Dideu Medichem Co. Ltd
2019-12-26 Ruxolitinib phosphate
1092939-17-7
US $0.10-0.10 / KG 1KG 99%+ 10000KG Shaanxi Dideu Medichem Co. Ltd
2019-12-25 Ruxolitinib phosphate
1092939-17-7
US $0.00-0.00 / KG 5g 99%+ 100 tons Shaanxi Dideu Medichem Co. Ltd

1092939-17-7(Ruxolitinib phosphate)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved